 |
|
Antiepileptics in the ElderlyPharmacoepidemiology and Pharmacokinetics
James C. Cloyd, PharmD;
Thomas E. Lackner, PharmD;
Ilo E. Leppik, MD
Arch Fam Med. 1994;3(7):589-598.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
1. Hauser WA, Hesdorffer DC, eds. Epilepsy: Frequency, Causes and Consequences. New York, NY: Demos Publications; 1990:1-92.
2. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-80. Epilepsia. 1991;32:429-445.
PUBMED
3. Katusic S, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol. 1990;27:89-95.
PUBMED
4. Harnisch JP. Zoster in the elderly: clinical, immunologic and therapeutic considerations. J Am Geriatr Soc. 1984;32:789-793.
PUBMED
5. Watson PN, Evans RJ. Postherpetic neuralgia: a review. Arch Neurol. 1986;43:836-840.
FREE FULL TEXT
6. Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry. 1990;51:115-118.
PUBMED
7. Krueger BR. Restless legs syndrome and periodic movements of sleep. Mayo Clin Proc. 1990;65:999-1006.
PUBMED
8. Rajput A, Offord KP, Beard CM, Kurland LT. Essential tremor in Rochester, Minnesota: a 45-year study. J Neurol Neurosurg Psychiatry. 1984;47:466-470.
FREE FULL TEXT
9. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med. 1991;114:956-966.
FREE FULL TEXT
10. Moore SR, Jones JK. Adverse drug reaction surveillance in the geriatric population: a preliminary review. In: Moore SR, Teal TW, eds. Proceedings of the Drug Information Association Workshop Geriatric Drug Use: Clinical and Social Perspectives. Elmsford, NY: Pergamon Press Inc; 1985:70-77. 11. Garnett WR, Carter BL, Pellock JM. Bioavailability of phenytoin administered with antacids. Ther Drug Monit. 1979;1:435-436.
12. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin, I, II. Clin Pharmacokinet. 1990;18:37-60, 131-150.
PUBMED
13. Itil TM, Soldatos C. Epileptogenic side effects of psychotropic drugs: practical recommendations. JAMA. 1980;244:1460-1463.
FREE FULL TEXT
14. Hansten PD, Horn JR, eds. Drug Interactions: A Clinical Perspective and Analysis of Current Developments. Vancouver, Wash: Applied Therapeutics Inc; 1993: 331-371. 15. Oles KS, Gal P, Penry JK, Tapscott WK. Use of antiepileptic drugs in the elderly population. Public Health Rep. 1987;102:335-337.
PUBMED
16. Institutionalized persons by age, sex, and type of institution. In: Census of Population and Housing: Special Tabulation Prepared for the Department of Health and Human Services. Washington, DC: US Bureau of the Census Population Division; December 1992. 17. Wallace SM, Verbeeck RK. Plasma protein binding of drugs in the elderly. Clin Pharmacokinet. 1987;12:41-72.
PUBMED
18. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31:155-163.
ABSTRACT
19. Verbeeck RK, Cardinal JA, Wallace SM. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol. 1984;27:91-97.
PUBMED
20. Greenblatt DJ. Reduced serum albumin concentrations in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc. 1979;27:20-22.
PUBMED
21. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age on liver volume and apparent liver blood flow in healthy man. Hepatology. 1989;9:297-301.
PUBMED
22. Tiula E, Neuvonen PJ. Antiepileptic drugs and alpha-1 acid glycoprotein. N Engl J Med. 1982;307:1148.
PUBMED
23. Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet. 1989;17:236-263.
PUBMED
24. Cusack BJ. Drug metabolism in the elderly. J Clin Pharmacol. 1988;28:571-576.
PUBMED
25. Greenblatt DJ, Shader RI, Harmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol. 1989;29:866-872.
PUBMED
26. Vestal RE, Norris AH, Tobin JD, Cohen DH, Shock MW, Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther. 1975;18:425-432.
PUBMED
27. Faich GA, Dreis M, Tomita D. National adverse drug reaction surveillance 1986. Arch Intern Med. 1988;148:785-787.
FREE FULL TEXT
28. Umstead GS, Morales M, McKercher PL. Comparison of total, free, and salivary phenytoin concentrations in geriatric patients. Clin Pharm. 1986;5:59-62.
PUBMED
29. Drinka PJ, Miller J, Voeks SK, Hamel P. Phenytoin binding in a nursing home. J Geriatr Drug Ther. 1988;3:73-82.
30. Hayes MJ, Langman MJS, Short AH. Changes in drug metabolism with increasing age, II: phenytoin clearance and protein binding. Br J Clin Pharmacol. 1975;2:73-79.
PUBMED
31. Edwards GB, Culbertson VL, Andresen GB, Rhodes PJ. Free phenytoin concentrations in geriatrics. J Geriatr Drug Ther. 1988;3:97-102.
32. Houghton GW, Richens A, Leighton M. Effects of age, height, weight and sex on serum phenytoin concentrations in epileptic patients. Br J Clin Pharmacol. 1975;2:251-256.
PUBMED
33. Sherwin AL, Loynd JS, Bock GW, Sokolowski CD. Effects of age, sex, obesity, and pregnancy on plasma diephenylhydantoin levels. Epilepsia. 1974;15:507-521.
PUBMED
34. Bender AD, Post A, Meier JP, Higson JE, Reichard G Jr. Plasma protein binding of drugs as a function of age in adult human subjects. J Pharm Sci. 1975;64:1711-1713.
PUBMED
35. Patterson M, Heazelwood R, Smithhurst B, Eadie MJ. Plasma protein binding of phenytoin in the aged: in-vivo studies. Br J Clin Pharmacol. 1982;13:423-425.
PUBMED
36. Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther. 1982;31:301-304.
PUBMED
37. Bach B, Hansen JM, Kampmann JP, Rasmussen SN, Skovsted L. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet. 1981;6:389-396.
PUBMED
38. Perucca E, Grimaldi R, Gatti G, Pirracchio S, Crema F, Frigo GM. Pharmaco-kinetics of valproic acid in the elderly. Br J Clin Pharmacol. 1984;17:665-669.
PUBMED
39. Bryson SM, Verma N, Scott PJW, Rubin PC. Pharmacokinetics of valproic acid in young and elderly subjects. Br J Clin Pharmacol. 1983;16:104-105.
PUBMED
40. Morselli PL. Carbamazepine: absorption, distribution and excretion. In: Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE, eds. Antiepileptic Drugs. 3rd ed. New York, NY: Raven Press; 1989:473-490. 41. Eadie MJ, Lander CM, Hooper WD, Tyrer JH. Factors influencing plasma phenobarbitone levels in epileptic patients. Br J Clin Pharmacol. 1977;4:41-47.
42. Martines C, Gatti G, Sasso E, Calzetti S, Perucca E. The disposition of primidone in elderly patients. Br J Clin Pharmacol. 1990;30:607-611.
PUBMED
43. Graves NM. Felbamate. Ann Pharmacother. 1993;27:1073-1081.
ABSTRACT
44. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, ed. New Trends in Epilepsy Management: The Role of Gabapentin. London, England: Royal Society of Medicine Services; 1993:41-46. 45. Peck AW. Clinical pharmacology of lamotrigine. Epilepsia. 1991;32(suppl_2):S9-S12.
PUBMED
46. Lambie DC, Caird FL. Phenytoin dosage in the elderly. Age Ageing. 1977;6:133-137.
FREE FULL TEXT
47. Troupin AS, Johannessen SI. Epilepsy in the elderly: a pharmacologic perspective. In: Smith DB, ed. Epilepsy: Current Approaches to Diagnosis and Treatment. New York, NY: Raven Press; 1990:141-153. 48. Bauer LA, Davis R, Wilensky A, Raisys V, Levy RH. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther. 1985;37:697-700.
PUBMED
49. MacKichan JJ, Duffner PK, Cohen ME. Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10, 11-epoxide in epileptic patients. Br J Clin Pharmacol. 1981;12:31-37.
PUBMED
50. Hockings N, Moody APJ, Davidson AVM, Davidson DLW. The effects of age on carbamazepine pharmacokinetics and adverse effects. Br J Clin Pharmacol. 1986;22:725-728.
PUBMED
51. Cook PJ, Flanagan R, James IM. Diazepam tolerance: effect of age, regular sedation and alcohol. BMJ. 1984;289:351-353.
FREE FULL TEXT
52. Crooks J, Stevenson IH. Drug response in the elderly: sensitivity and pharmacokinetic considerations. Age Ageing. 1981;10:73-80.
FREE FULL TEXT
53. Theodore WH. Clinical pharmacology of antiepileptic drugs: selected topics. Neurol Clin. 1990;8:177-191.
PUBMED
54. Bollini P, Riva R, Albani F, et al. Decreased phenytoin levels during antine-oplastic therapy: a case report. Epilepsia. 1983;24:75-78.
PUBMED
55. Neef C, de Voogd-van den Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther. 1988;43:372-375.
PUBMED
56. Berg MJ, Ebert BE, Rivey MP, Schottelius DD. Utilization of Km for phenytoin dosage after folate addition to patients' regimen. Ther Drug Moint. 1987;9:304-305.
57. Haley CJ, Nelson J. Phenytoin-enteral feeding interaction. Ann Pharmacother. 1989;23:796-798.
PUBMED
58. Sandor P, Sellers EM, Dumbrell M, Khouse V. Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. Clin Pharmacol Ther. 1981;30:390-397.
PUBMED
59. Cold JA, Wells BG, Froemming JH. Seizure activity associated with antipsychotic therapy. Ann Pharmacother. 1990;24:601-606.
ABSTRACT
60. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? a novel assessment technique. JAMA. 1989;261:3273-3277.
FREE FULL TEXT
|
